Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 5/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1644634 | 1.00 | HTR2A (0.51) | HTR2AHTR2CHTR2BTP53MDM2 | |
| SCHEMBL1645778 | 1.00 | HTR2A (0.51) | HTR2AHTR2CHTR2BTP53MDM2 | |
| SCHEMBL13598560 | 0.96 | HTR2A (0.51) | HTR2AHTR2CHTR2BTP53MDM2 | |
| SCHEMBL9781187 | 0.83 | HTR2A (0.55) | HTR2AHTR2CHTR2BTP53MDM2 | |
| SCHEMBL15542074 | 0.81 | HTR2C (0.62) | HTR2AHTR2CHTR2BSLC6A3TAAR1 | |
| SCHEMBL7090511 | 0.81 | HTR2C (0.62) | HTR2AHTR2CHTR2BSLC6A3TAAR1 | |
| SCHEMBL7654609 | 0.81 | HTR2C (0.62) | HTR2AHTR2CHTR2BSLC6A3TAAR1 | |
| SCHEMBL5521413 | 0.81 | HTR2C (0.62) | HTR2AHTR2CHTR2BSLC6A3TAAR1 | |
| SCHEMBL1646738 | 0.79 | KDM1A (0.68) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| SCHEMBL1645762 | 0.79 | HTR2A (0.50) | HTR2AHTR2CHTR2BTAAR1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4666533-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| US-7411093-B2 | Aminocycloalkanes as DPP-IV inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-08-12 | — | — | US | claimed |
| JP-2008524279-A | — | — | 2008-07-10 | — | — | JP | claimed |
| CN-101084184-A | Cycloalkylamine derivative | HOFFMANN LA ROCHE (CH) | 2007-12-05 | — | — | CN | claimed |
| EP-1833782-A1 | CYCLOALKYLAMINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-19 | — | — | EP | claimed |
| WO-2006066770-A1 | CYCLOALKYLAMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | claimed |
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | US | claimed |
| EP-1833782-B1 | CYCLOALKYLAMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-7411093-B2 | Aminocycloalkanes as DPP-IV inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-08-12 | — | — | US | disclosed |
| CN-101084184-A | Cycloalkylamine derivative | HOFFMANN LA ROCHE (CH) | 2007-12-05 | — | — | CN | disclosed |
| EP-1833782-A1 | CYCLOALKYLAMINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006066770-A1 | CYCLOALKYLAMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | DPP4, DPP7, DPP3 | HTR2A 1865/4885HTR2C 1770/4885HTR2B 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.